Boehringer Ingelheim announces European Medicines Agency’s filing acceptance and validation of marketing authorization application for spesolimab in generalized pustular psoriasis
29.10.2021 10:00:00 EEST | Business Wire | Press release
Boehringer Ingelheim announced today that the company’s marketing authorization application (MAA) for the treatment of flares in generalized pustular psoriasis (GPP), has been validated and is now under evaluation with the European Medicines Agency (EMA).
“GPP is a rare, life-threatening neutrophilic skin disease characterized by painful, sterile pus-filled blisters, that can suddenly appear over the body,” said Dr. Janine Lamar, Global Spesolimab Lead at Boehringer Ingelheim. “Despite its name, GPP is very different to the more common plaque psoriasis. With no approved treatments in the EU for GPP flares, acceptance of the application for review of spesolimab brings us one step closer to providing a targeted treatment for people with this distressing, unpredictable and painful skin condition.”
GPP is characterized by episodes of widespread eruptions of painful, sterile pustules (blisters of non-infectious pus).1,2,3 The inflammation can also affect other parts of the body and can lead to infections or other organ complications that may be life-threatening.
There is a high unmet need for treatments that can rapidly and completely resolve the symptoms of GPP flares. Flares greatly affect a person’s quality of life4 and can lead to hospitalization with life-threatening complications, such as heart failure, renal failure, sepsis and even death.5
The marketing authorization application was based on the 12 week Effisayil-1 trial; a multi-center, double-blind, randomized, placebo-controlled trial that evaluated efficacy, safety, and tolerability of spesolimab (single dose 900 mg spesolimab i.v., with the option of a 2nd dose if symptoms persisted on Day 8) in patients experiencing a GPP flare.6 The study demonstrated superiority over placebo in pustular clearance after one week of treatment.
Please click on the following link for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/ema-filing-acceptance-and-validation-spesolimab
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211029005027/en/
Contact information
Boehringer Ingelheim
Corporate Communications
Media + PR
Dr Julia Faass
Phone: +49 (6132) 77 95614
Fax: +49 (6132) 77 6601
Email: press@boehringer-ingelheim.com
Additional information
www.boehringer-ingelheim.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Prodalim Reports Q3 2026 Results, with Growth in its Specialty Ingredients & Solutions Business and Solos Activity Net Profit and Cashflow from Operating Activities9.11.2026 12:18:00 EET | Press release
Regulatory News: Tsahi Barak, Chairman of the Board and CEO of the Company, commented: "We are pleased to report another quarter of growth across all key operating parameters, alongside an important strategic acquisition. We continue to make substantial investments in production infrastructure, innovation and the recruitment of key talents. We are only beginning to see the fruits of these moves, reflected in the continued profitable growth of our Specialty Ingredients & Solutions (SIS) business and in the acceleration of growth at Solos, alongside moderate growth and improved profitability in our Juice Solutions business during the quarter. The acquisition of BOK that we announced a few days ago is a strategic step that deepens our activity with the wine industry and expands our basket of natural products based on wine-industry by-products, all while maintaining circular economy principles. The move will increase sales turnover, improve profitability and expand the Company’s product an
Logistics Reply named a Leader in the IDC MarketScape: Worldwide Warehouse Management for Retail and Manufacturing9.11.2026 11:00:00 EET | Press release
Logistics Reply, the Reply Group company specialised in software solutions for supply chain execution and warehouse management, has been positioned in the Leaders Category of the IDC MarketScape: Worldwide Warehouse Management for Retail 2026 Vendor Assessment (doc #US53701926, October 2026) as well as in the IDC MarketScape: Worldwide Warehouse Management for Manufacturing 2026 Vendor Assessment (doc #US53013526, October 2026). The reports evaluate vendors based on strategy and product capabilities, looking at both quantitative and qualitative criteria. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261109197861/en/ Logistics Reply, the Reply Group company specialised in software solutions for supply chain execution and warehouse management, has been positioned in the Leaders Category of the IDC MarketScape: Worldwide Warehouse Management for Retail and Manufacturing. LEA ReplyTM is Logistics Reply’s cloud-native warehouse
SWISSto12 passes critical design review of dual-band 5G antennas for UNIVITY satellites9.11.2026 10:00:00 EET | Press release
SWISSto12, a leading enabler of the new space economy, today announced it has passed the Critical Design Review (CDR) for the S- and Ka-band phased array antennas for UNIVITY’s 5G non-terrestrial network (NTN) demonstration satellites. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261109823601/en/ SWISSto12's S- and Ka-band phased array antennas pass Critical Design Review SWISSto12 is developing two active antennas for UNIVITY: an S-band direct radiating array (DRA) for direct-to-device services, connecting standard 5G phones straight to the satellite, and a Ka-band DRA operating at 26 GHz for broadband services and feeder links. Both are built for 5G NTN applications, allowing one single satellite to carry both broadband and direct-to-device 5G connectivity. These developments are part of UNIVITY's uniShape program, institutionally supported by France 2030 and the French Space Agency (CNES). This dual capability supports
Avanzanite Announces Exclusive Licence Agreement to Commercialise Zemcelpro ® in Europe9.11.2026 08:00:00 EET | Press release
Avanzanite Bioscience B.V. (“Avanzanite” or “Company”) a European pharmaceutical company focused on rare diseases, today announced an exclusive licence agreement with Montreal-based Cordex Biologics, an ExCellThera company (“ExCellThera”), a leader in enhanced blood stem cell therapies, to commercialise Zemcelpro®. Zemcelpro received conditional marketing authorisation from the European Commission on 25 August 2025 for the treatment of adult patients with haematological malignancies requiring an allogeneic haematopoietic stem cell transplant (allo-HSCT) following myeloablative conditioning for whom no other type of suitable donor cells is available. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261108032164/en/ Adam Plich, Co-founder and CEO, Avanzanite Bioscience Under the agreement, Avanzanite will lead commercialisation across 32 countries including the European Economic Area, UK and Switzerland. Avanzanite will become t
Arrow Electronics launches new business Capstone to increase focus on IP&E solutions9.11.2026 08:00:00 EET | Press release
Arrow Electronics, Inc. (NYSE:ARW) today announced the launch of Capstone, a global business dedicated to interconnect, passive and electromechanical (IP&E) products, solutions and services. With Capstone, Arrow creates a focused and specialized go-to-market approach for IP&E as that technology segment becomes more critical for system performance, reliability and supply continuity. Capstone is designed to make IP&E easy to specify, source and scale. Customers will gain the benefit of dedicated IP&E coverage, fast decision-making and broad execution support across the full on-board and off-board electrical system. By operating under a focused brand, Capstone gives customers more specialized support from design-in through production. The result is a strong platform for improving design choices, reducing execution risk and helping customers scale. The launch of Capstone is part of a broader realignment of Arrow’s global components business, moving from a geography operating model to a tec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom